+86 137 2013 4139
+86 137 2013 4139
Wuhan Jingkang en Biomedical Technology Co., Ltd. is a high-tech enterprise specializing in the research & development, production, custom synthesis and sales of various pharmaceutical materials, including API, electronic materials, pharmaceutical intermediates, Small-molecule inhibitors and drug impurity reference standards. the company boasts research and development center, pilot plant, production base, stable collaborative factories, and an experienced international trade department.
Wuhan Jingkang en Biomedical Technology has cultivated long-standing partnerships with well-known pharmaceutical chemical companies, research institutions, and university laboratories, both domestically and internationally.
We supply products with reliable quality, international regulations and full documents support!
The products we supply mainly include pharmaceutical raw materials, pharmaceutical intermediates, electronic materials, organic synthesis building block and drug impurity. Customized synthesis business, with a professional R&D department, our production capacity from gram level to tonnage level.
Wuhan Jingkang en Biomedical Technology Co., Ltd. is committed to continuous innovation, providing the top-quality products and services for the development of global scientific research with a professional technical team, rigorous research attitude, and enthusiastic customer service !
[Core Values]
"Gratitude" ,"Customer-Centric", "Continuous Innovation" and "Proactive Action".
Apr. 21, 2025
The global pharmaceutical intermediates market is set for significant expansion, with revenue expected to grow from USD 36,620.2 million in 2025 to USD 57,031.9 million by 2035, at a steady CAGR of 4.5%. In 2024, the market is valued at USD 35,081.4 million, highlighting the sector's accelerating momentum.
Apr. 14, 2025
MRTX-1133 is one of the first potent, selective KRAS G12D inhibitors that binds noncovalently to the S-IIP of the active and inactive states of KRAS G12D [33]. Preclinical studies showed significant efficacy, with tumor regression in xenograft mouse models occurring in a dose-dependent manner [34].
Apr. 07, 2025
Signal transducer and activator of transcription 5 (STAT5) is an attractive therapeutic target, but successful targeting of STAT5 has proved to be difficult. Here we report the development of AK-2292 as a first, potent and selective small-molecule degrader of both STAT5A and STAT5B isoforms.
Menu
Contact Us
Tel: +86 137 2013 4139
E-mail: orders@jknbiochem.com
Add.:Room 2120, Office Building 2, No.1 Baisha Fifth Road, Hongshan District, Wuhan City, Hubei Province, China
Get In Touch
Get In Touch
